Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$9.84 +11.2%	$8.14	$3.76 ▼ $46.80	$54.44M	2.77	57,580 shs	153,290 shs
EDIT Editas Medicine	$2.73 +2.2%	$2.62	$0.91 ▼ $4.12	$240.09M	2.19	2.17 million shs	849,171 shs
ENGN enGene	$3.91 +1.3%	$3.62	$2.65 ▼ $11.00	$197.27M	-0.41	99,230 shs	42,292 shs
PBYI Puma Biotechnology	$5.22 +2.2%	$3.71	$2.22 ▼ $6.07	$257.40M	1.3	865,997 shs	807,250 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	+11.19%	+29.64%	+7.89%	+78.91%	-28.44%
EDIT Editas Medicine	+2.25%	-7.77%	-18.75%	+76.13%	-33.09%
ENGN enGene	+1.30%	+8.31%	+1.30%	-7.78%	-36.42%
PBYI Puma Biotechnology	+2.15%	-1.88%	+50.43%	+61.61%	+93.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.526 of 5 stars	3.5	4.0	4.8	3.3	1.7	0.6
EDIT Editas Medicine	4.2137 of 5 stars	3.1	4.0	4.3	1.7	2.5	0.6
ENGN enGene	3.3089 of 5 stars	3.5	5.0	0.0	1.7	2.5	0.6
PBYI Puma Biotechnology	4.1554 of 5 stars	3.5	1.0	0.0	3.3	4.2	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$50.00	408.13% Upside
EDIT Editas Medicine	2.23	Hold	$5.10	86.81% Upside
ENGN enGene	3.00	Buy	$23.29	495.54% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	34.10% Upside

Current Analyst Ratings Breakdown

Latest ALGS, ENGN, PBYI, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.94M	15.36	N/A	N/A	$16.56 per share	0.59
EDIT Editas Medicine	$38.90M	6.31	N/A	N/A	$0.21 per share	13.00
ENGN enGene	N/A	N/A	N/A	N/A	$5.35 per share	N/A
PBYI Puma Biotechnology	$238.06M	1.10	$0.87 per share	6.00	$2.08 per share	2.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$131.21M	-$19.79	N/A	N/A	N/A	-2,337.24%	-22.41%	-12.09%	11/5/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	9/10/2025 (Estimated)
PBYI Puma Biotechnology	$30.28M	$0.98	5.33	13.74	N/A	20.38%	53.15%	23.51%	11/6/2025 (Estimated)

Latest ALGS, ENGN, PBYI, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2025	Q3 2025	ENGN enGene	-$0.5084	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/6/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	-$1.53	+$0.82	-$1.53	$0.43 million	$0.97 million
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
ENGN enGene	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	6.31	6.31
EDIT Editas Medicine	N/A	2.77	2.77
ENGN enGene	0.09	12.66	12.66
PBYI Puma Biotechnology	0.10	1.73	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
EDIT Editas Medicine	71.90%
ENGN enGene	64.16%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
EDIT Editas Medicine	2.10%
ENGN enGene	10.40%
PBYI Puma Biotechnology	23.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.15 million	5.86 million	No Data
EDIT Editas Medicine	230	89.92 million	88.03 million	Optionable
ENGN enGene	31	51.10 million	45.79 million	N/A
PBYI Puma Biotechnology	200	50.37 million	38.64 million	Optionable

ALGS, ENGN, PBYI, and EDIT Headlines

Recent News About These Companies

Puma Biotechnology (NASDAQ:PBYI) Upgraded to Buy at Wall Street Zen

August 19 at 2:47 AM | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Upgraded by Wall Street Zen to Buy Rating

August 18, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

August 16, 2025 | marketbeat.com

Additional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong Earnings

August 15, 2025 | finance.yahoo.com

Puma Biotechnology Reports Strong Q2 2025 Earnings

August 13, 2025 | msn.com

Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT

August 12, 2025 | msn.com

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

August 12, 2025 | zacks.com

Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?

August 12, 2025 | zacks.com

Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

August 10, 2025 | finance.yahoo.com

Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Mackenzie Financial Corp Acquires 79,060 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

August 9, 2025 | marketbeat.com

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

August 8, 2025 | zacks.com

Puma (PBYI) Q2 Revenue Rises 11%

August 8, 2025 | fool.com

Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Puma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years ago

August 2, 2025 | finance.yahoo.com

Puma Biotechnology (PBYI) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

July 30, 2025 | marketbeat.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

July 24, 2025 | businesswire.com

Alessandra Cesano Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

July 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, ENGN, PBYI, and EDIT Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$9.84 +0.99 (+11.19%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$9.77 -0.07 (-0.71%)

As of 08/21/2025 06:56 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.73 +0.06 (+2.25%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$2.74 +0.01 (+0.22%)

As of 08/21/2025 07:47 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

enGene NASDAQ:ENGN

$3.91 +0.05 (+1.30%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$4.03 +0.12 (+3.07%)

As of 08/21/2025 07:05 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Puma Biotechnology NASDAQ:PBYI

$5.22 +0.11 (+2.15%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$5.31 +0.09 (+1.72%)

As of 08/21/2025 07:34 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time